Does WellCare Cover Forteo or Teriparatide in 2026?

Editorial evidence status: Rebuilt from WellCare's current plan documents, CMS coverage-determination rules, the FDA label, and primary trial evidence on August 29, 2026. A licensed clinician has not approved this revision. It remains in Medical/expert approval required status.

The useful answer is product-specific, not a blanket yes or no

WellCare publishes different formularies for different plans, states, and benefit designs. A drug that is covered by one WellCare plan can be absent, differently tiered, or restricted by another. Even within one plan, a brand and its generic or follow-on product can have different status.

The August 1, 2026 WellCare Classic PDP formulary provides a concrete example:

Those facts come from one nationally marketed PDP document, not a promise about every WellCare plan. The same document says benefits, formulary placement, networks, and cost sharing may change and instructs members to use the current plan materials. [1]

WellCare says formulary coverage generally depends on medical necessity, use of a network pharmacy, and compliance with the plan's other rules [1]. This is an attributed paraphrase of the first paragraph under “What is the Wellcare Classic (PDP) formulary?” on printed page I/PDF page 2, not an endorsement of this page or a guarantee that an individual claim will be paid.

Figure 1. The exact-product coverage check. HealthRX.com editorial synthesis of the August 2026 WellCare Classic PDP formulary and CMS coverage-determination process. It shows a verification sequence, not a universal WellCare policy. Medical review is pending.

Check four fields before discussing cost

1. Exact plan and year. Use the plan name and contract details on the member card. A generic “WellCare formulary” search can land on a different plan.
2. Exact product and NDC. Search Forteo, teriparatide, and Bonsity separately. If the document limits the covered NDC, give that detail to the pharmacy.
3. Restriction code. In the verified Classic PDP example, both listed teriparatide products require prior authorization and have quantity limits. “Covered” therefore does not mean “covered without review.”
4. Cost sharing. Tier 5 is a specialty tier in that plan, but a member's dollar cost depends on the Evidence of Coverage, pharmacy, deductible, accumulated out-of-pocket spending, and eligibility for assistance.

Do not quote a national cash-price estimate as the member's WellCare cost. A formulary can establish listing and restrictions; it cannot establish an individual's final bill.

What a coverage request needs to answer

The plan's prior-authorization criteria are the controlling document. A useful submission usually connects the patient to the FDA-labeled population and explains why lower-cost options are unsuitable, ineffective, or already tried. The current FDA label covers postmenopausal women at high fracture risk, men with primary or hypogonadal osteoporosis at high fracture risk, and people with glucocorticoid-associated osteoporosis at high fracture risk. [2]

A prescriber submission should make the case legible:

• diagnosis and the dated DXA report;
• fracture history, including imaging when relevant;
• prior osteoporosis medicines, dates, response, and reason for stopping;
• contraindication or intolerance documentation when it is the reason an alternative is unsuitable;
• the requested product, strength, NDC, and quantity;
• the current plan criterion being satisfied or the medical reason for an exception.

This is more defensible than presenting invented universal thresholds such as a mandatory T-score, a fixed number of months of bisphosphonate use, or a required prescriber specialty. Those conditions can vary by plan and indication.

A current label correction: two years is not an absolute lifetime ban

Older coverage guides often state that teriparatide has an absolute 24-month lifetime maximum. The current Forteo label is more qualified: “Use of FORTEO for more than 2 years during a patient's lifetime should only be considered” when high fracture risk persists or returns. [2]

That 15-word regulatory excerpt is from FDA-approved prescribing information, revised February 2024, section 2.3, page 2. It clarifies labeling; it does not tell WellCare to approve treatment beyond two years. A plan can still apply its own evidence-based duration criteria, and the prescriber must make an individualized benefit-risk case.

If the pharmacy says Forteo is not covered

First determine whether the rejection is about the brand, the NDC, prior authorization, quantity, or the member's pharmacy network. Those failures lead to different fixes.

CMS treats a decision about prior authorization, step therapy, quantity, formulary exceptions, and disputed cost sharing as a coverage determination. For Part D benefit requests, the standard deadline is generally 72 hours and the expedited deadline 24 hours after the necessary supporting material is received. [3]

If the decision is unfavorable, follow the instructions in the notice. As of 2026, a Part D redetermination request generally must be filed within 65 calendar days; the plan must decide within seven calendar days for a standard request or 72 hours for an expedited request. [4]

Why coverage can still be clinically consequential

Teriparatide is an anabolic therapy, not simply another formulation of an oral bisphosphonate. In the VERO randomized trial of 1,360 postmenopausal women with severe osteoporosis, new radiographic vertebral fractures occurred in 5.4% of the teriparatide group and 12.0% of the risedronate group over 24 months. [5]

That trial does not prove that every applicant needs teriparatide, nor does it override plan criteria. It explains why an exception request should connect the medicine's distinct clinical role to the patient's actual fracture risk instead of relying on the brand name or cost alone.